title: Reply from authors re: David Margel. Metformin to prevent prostate cancer: a call to unite. Eur urol 2014;66:1021-2.
authors.affiliation: Department of Urology, Massachusetts General Hospital, Boston, MA, USA. Electronic address: preston.mark@gmail.com.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Preston
authors.affiliation: Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
authors.forename: Julie
authors.initials: J
authors.lastname: Batista
authors.affiliation: The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Rodney H
authors.initials: RH
authors.lastname: Breau
authors.affiliation: Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Hans-Olov
authors.initials: HO
authors.lastname: Adami
authors.affiliation: Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
authors.forename: Henrik T
authors.initials: HT
authors.lastname: Sørensen
mesh_terms: D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000453:epidemiology*
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin